Deng P S, Hatefi Y, Chen S
Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010.
Biochemistry. 1990 Jan 30;29(4):1094-8. doi: 10.1021/bi00456a036.
N-Arylazido-beta-alanyl-NAD+ [N3'-O-(3-[N-(4-azido-2-nitrophenyl)amino]propionyl)NAD+] has been prepared by alkaline phosphatase treatment of arylazido-beta-alanyl-NADP+ [N3'-O-(3-[N-(4-azido-2-nitrophenyl)amino]propionyl)NADP+]. This NAD+ analogue was found to be a potent competitive inhibitor (Ki = 1.45 microM) with respect to NADH for the purified bovine heart mitochondrial NADH dehydrogenase (EC 1.6.99.3). The enzyme was irreversibly inhibited as well as covalently labeled by this analogue upon photoirradiation. A stoichiometry of 1.15 mol of N-arylazido-beta-alanyl-NAD+ bound/mol of enzyme, at 100% inactivation, was determined from incorporation studies using tritium-labeled analogue. Among the three subunits, 0.85 mol of the analogue was bound to the Mr = 51,000 subunit, and each of the two smaller subunits contained 0.15 mol of the analogue when the dehydrogenase was completely inhibited upon photolysis. Both the irreversible inactivation and the covalent incorporation could be prevented by the presence of NADH during photolysis. These results indicate that N-arylazido-beta-alanyl-NAD+ is an active-site-directed photoaffinity label for the mitochondrial NADH dehydrogenase, and are further evidence that the Mr = 51,000 subunit contains the NADH binding site. Previous studies using A-arylazido-beta-alanyl-NAD+ [A3'-O-(3-[N-(4-azido-2-nitrophenyl)amino]propionyl)NAD+] demonstrated that the NADH binding site is on the Mr = 51,000 subunit [Chen, S., & Guillory, R. J. (1981) J. Biol. Chem. 256, 8318-8323]. Results are also presented to show that N-arylazido-beta-alanyl-NAD+ binds the dehydrogenase in a more effective manner than A-arylazido-beta-alanyl-NAD+.
通过碱性磷酸酶处理芳基叠氮基-β-丙氨酰-NADP⁺[N³'-O-(3-[N-(4-叠氮基-2-硝基苯基)氨基]丙酰基)NADP⁺]制备了N-芳基叠氮基-β-丙氨酰-NAD⁺[N³'-O-(3-[N-(4-叠氮基-2-硝基苯基)氨基]丙酰基)NAD⁺]。已发现这种NAD⁺类似物是纯化的牛心线粒体NADH脱氢酶(EC 1.6.99.3)对NADH的一种强效竞争性抑制剂(Ki = 1.45 μM)。在光照射下,该类似物会使该酶不可逆地受到抑制并进行共价标记。通过使用氚标记的类似物进行掺入研究,确定在100%失活时,每摩尔酶结合1.15摩尔的N-芳基叠氮基-β-丙氨酰-NAD⁺。在三个亚基中,当脱氢酶在光解时完全被抑制时,0.85摩尔的类似物与Mr = 51,000的亚基结合,两个较小的亚基各含有0.15摩尔的类似物。在光解过程中,NADH的存在可以防止不可逆失活和共价掺入。这些结果表明N-芳基叠氮基-β-丙氨酰-NAD⁺是线粒体NADH脱氢酶的活性位点导向的光亲和标记,并且进一步证明Mr = 51,000的亚基包含NADH结合位点。先前使用A-芳基叠氮基-β-丙氨酰-NAD⁺[A³'-O-(3-[N-(4-叠氮基-2-硝基苯基)氨基]丙酰基)NAD⁺]的研究表明NADH结合位点在Mr = 51,000的亚基上[陈,S.,& 吉洛里,R. J.(1981年)《生物化学杂志》256,8318 - 8323]。还给出的结果表明N-芳基叠氮基-β-丙氨酰-NAD⁺比A-芳基叠氮基-β-丙氨酰-NAD⁺以更有效的方式结合脱氢酶。